BioCentury
ARTICLE | Finance

Hillhouse-backed $160M series B round to drive Genor’s first candidate to the market

June 2, 2020 2:00 AM UTC
Updated on Jun 2, 2020 at 8:54 PM UTC

Genor plans to establish a commercial team and take its first checkpoint inhibitor to market for a new indication after raising a $160 million series B round led by existing investor Hillhouse Capital.

New investors Temasek, CR-CP Life Science Fund, Haitong Capital and Cavenham PE participated in the financing...